Clinical Report: ESGAR Guidelines on Noninvasive Diagnosis of Hepatocellular Carcinoma
Overview
ESGAR practice guidelines emphasize noninvasive diagnosis of hepatocellular carcinoma (HCC) in high-risk patients using contrast-enhanced CT or MRI, highlighting key imaging criteria to optimize specificity and sensitivity. Contrast-enhanced ultrasound serves as a supplementary tool in specialized centers. The guidelines also delineate patient populations appropriate for noninvasive diagnosis and recommend imaging modality selection based on availability and patient factors.
Background
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and a leading cause of cancer-related mortality worldwide. Most HCC cases occur in patients with cirrhosis or chronic liver disease, with risk factors including chronic hepatitis B and C, nonalcoholic fatty liver disease, and alcohol abuse. Noninvasive diagnosis of HCC is possible in high-risk patients through characteristic imaging features on contrast-enhanced CT, MRI, or ultrasound, avoiding the need for histopathology. Multiple international guidelines provide diagnostic criteria reflecting regional epidemiology and resource availability.
Data Highlights
Imaging Modality
Specificity for HCC Diagnosis
Sensitivity for HCC Diagnosis
CT
>90%
48–66%
MRI
>90%
61–82%
Key Findings
Noninvasive diagnosis of HCC is applicable only in patients at high risk, including those with cirrhosis, chronic hepatitis B, or prior/current HCC history.
Contrast-enhanced CT or MRI are the recommended imaging modalities, with MRI preferred for higher sensitivity, especially for small lesions.
Key imaging criteria include lesion size, non-rim arterial phase hyperenhancement, non-peripheral washout, enhancing capsule, and threshold growth.
Hepatobiliary phase hypointensity increases sensitivity but reduces specificity due to overlap with non-HCC lesions.
Lesions with targetoid appearance are atypical for HCC and suggest non-HCC malignancy.
Contrast-enhanced ultrasound is useful as a problem-solving tool in experienced centers but is limited by operator dependency and lesion accessibility.
Clinical Implications
Clinicians should apply noninvasive diagnostic criteria only in patients meeting high-risk definitions to maintain diagnostic specificity. MRI with extracellular contrast agents is preferred for lesion characterization when available, while CT remains a valid alternative. Contrast-enhanced ultrasound can aid diagnosis in select cases but requires expertise. Understanding imaging features and patient risk profiles is essential to avoid misdiagnosis and unnecessary biopsies.
Conclusion
ESGAR guidelines provide evidence-based recommendations for the noninvasive diagnosis of HCC, emphasizing appropriate patient selection and imaging criteria to optimize diagnostic accuracy. These practices support timely and accurate diagnosis, facilitating effective management of patients at risk for HCC.
References
ESGAR Practice Guidelines 2024 -- Key Insights on Diagnosing Hepatocellular Carcinoma
